Novo Nordisk Announces Partnership with OpenAI

Novo Nordisk A/S (NYSE:NVO) is included among the 10 Best Affordable Blue Chip Stocks to Buy Now.

Novo Nordisk A/S (NYSE:NVO) is a leading global healthcare company, founded in 1923 and headquartered in Denmark.

Novo Nordisk A/S (NYSE:NVO) announced on April 14 that it was partnering with OpenAI to deploy artificial intelligence across its business. The strategic partnership will allow the Wegovy-maker to better use AI to analyze complex datasets, identify promising new drugs, and reduce the time it takes for a medicine to move from the research stage to patient use.

Sam Altman’s OpenAI will assist Novo Nordisk A/S (NYSE:NVO) in training its global workforce, enhancing AI literacy, and boosting productivity across departments. The drugmaker revealed that pilot programmes would begin across ‌research ⁠and development, manufacturing, and commercial operations, with full integration planned by the end of this year.

Novo Nordisk A/S (NYSE:NVO) also clarified that the initiative was not intended to ⁠cut its current workforce, but to lift the productivity of its employees and curb the pace of future hiring.

Mike Doustdar, President and CEO of Novo Nordisk A/S (NYSE:NVO), commented:

“This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare. There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives. Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever. This means discovering new therapies and bringing them to market faster than ever before.”

READ NEXT: 12 Most Undervalued Natural Gas Stocks to Buy Now and 15 Best Blue Chip Stocks to Buy Now

Disclosure: None. Follow Insider Monkey on Google News.